The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors
Open Access
- 2 December 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (2) , 2083-2095
Abstract
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumorsKeywords
This publication has 109 references indexed in Scilit:
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase ComplexCancer Discovery, 2015
- Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumorsPediatric Blood & Cancer, 2013
- PI3K in cancer–stroma interactions: bad in seed and ugly in soilOncogene, 2013
- Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing programPediatric Blood & Cancer, 2012
- Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours (Retracted Article)2012
- Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in MedulloblastomaScience Translational Medicine, 2010
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyJournal of Hematology & Oncology, 2009
- Rarity ofPTENdeletions andEGFRamplification in malignant gliomas of childhood: results from the Children’s Cancer Group 945 cohortJournal of neurosurgery. Pediatrics, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human GliomasJournal of Clinical Oncology, 2004